Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Non-Current Debt (2016 - 2019)

Fate Therapeutics' Non-Current Debt history spans 8 years, with the latest figure at $9.5 million for Q2 2019.

  • For Q2 2019, Non-Current Debt fell 26.23% year-over-year to $9.5 million; the TTM value through Jun 2019 reached $9.5 million, down 26.23%, while the annual FY2018 figure was $12.4 million, 15.95% down from the prior year.
  • Non-Current Debt reached $9.5 million in Q2 2019 per FATE's latest filing, down from $11.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $16.4 million in Q1 2015 to a low of $1.1 million in Q1 2017.
  • Average Non-Current Debt over 5 years is $10.3 million, with a median of $11.3 million recorded in 2018.
  • Peak YoY movement for Non-Current Debt: crashed 87.57% in 2017, then soared 1201.48% in 2018.
  • A 5-year view of Non-Current Debt shows it stood at $10.7 million in 2015, then plummeted by 76.6% to $2.5 million in 2016, then skyrocketed by 492.08% to $14.8 million in 2017, then dropped by 15.95% to $12.4 million in 2018, then fell by 23.92% to $9.5 million in 2019.
  • Per Business Quant, the three most recent readings for FATE's Non-Current Debt are $9.5 million (Q2 2019), $11.0 million (Q1 2019), and $12.4 million (Q4 2018).